NCT04909034View on ClinicalTrials.gov

A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

October 23, 2024

Study Completion Date

November 30, 2024

Conditions

NSCLC Stage IIIB~IV

Interventions

DRUG

MS-20

Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans

DRUG

Placebo

Oral solution without active ingredients

Trial Locations (7)

110

Taipei Medical University Hospital, Taipei

116

Taipei Municipal Wanfang Hospital, Taipei

235

Ministry of Health and Welfare Shuang-Ho Hospital, Taipei

333

Chang Gung Memorial Hospital Linkou Branch, Taoyuan District

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

824

E-Da Hospital, Kaohsiung City

833

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors

lead

Microbio Co Ltd

INDUSTRY

NCT04909034 - A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter